Advent Therapeutics Inc.

Lumberville, PA

UEI
VMY3LNAJHQN9
CAGE
7XAP2
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Hispanic American Owned
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
6500 Old Carversville Rd, Lumberville, PA 18933, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Advancing small molecule read through compounds to prevent and/or treat heritable pulmonary artery hypertension R41HL152915 National Heart Lung and Blood Institute (NIH) $504,262
Aerosolized vitamin a: impact on neonatal lung maturation, hyperoxic lung injury and bronchopulmonary dysplasia R44HL142353 National Heart Lung and Blood Institute (NIH) $12,186,685
Aerosolized vitamin a impact on lung maturation and hyperoxic neonatal lung injury R43HL142353 National Heart Lung and Blood Institute (NIH) $225,000

Quick answers

Is Advent Therapeutics Inc. registered in SAM.gov?

Yes. Advent Therapeutics Inc.'s SAM.gov registration is active through January 5, 2027.

What is Advent Therapeutics Inc.'s most recent federal award?

Advent Therapeutics Inc.'s most recent federal grant award is Advancing small molecule read through compounds to prevent and/or treat heritable pulmonary artery hypertension (R41HL152915), from National Heart Lung and Blood Institute (NIH), on August 15, 2020.

On GovTribe

See Advent Therapeutics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login